Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 951-956

  Qian Yy, Mary ^a   Yuwei J, Rong ^a   Angus, Peter ^a   Schelleman, Tony ^a   Johnson, Lynne ^a   Gow, Paul ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

AFP; Australia; Cirrhosis; Cost; Efficacy; Hepatoma; Hospital; Screening; Ultrasound

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; AFP PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER DIAGNOSIS; CANCER SCREENING; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; DIAGNOSTIC TEST; ECHOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; AMBULATORY CARE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HEPATITIS B; HOSPITAL COST; LIVER; LIVER NEOPLASMS; MASS SCREENING; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROGRAM EVALUATION; TIME; VERY ELDERLY; VIROLOGY; ALPHA FETOPROTEIN BLOOD LEVEL; ASSESSMENT OF HUMANS; AUSTRALIAN; CANCER INCIDENCE; CANCER RADIOTHERAPY; CHRONIC HEPATITIS B; CONTROLLED STUDY; DOPPLER FLOWMETRY; MILAN CRITERIA;

AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; AMBULATORY CARE; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS B, CHRONIC; HOSPITAL COSTS; HOSPITALS, TEACHING; HUMANS; INCIDENCE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; TIME FACTORS; VICTORIA;

EID: 77951727877     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06203.x     Document Type: Article

References (23)

1. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med. J. Aust. 2000 173 : 403 405.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999 340 : 745 750.
3. Gane E, McCall J. Management of hepatocellular carcinoma in New Zealand. N. Z. Med. J. 2000 113 : 172 175.
4. Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J. Gastroenterol. 2006 12 : 4656 4659.
5. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004 130 : 417 422.
6. Roberts SK, Kemp W. Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation. J. Gastroenterol. Hepatol. 2007 22 : 191 196.
7. Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008 14 : 4300 4308.
8. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999 340 : 745 750.
9. Taylor-Robinson SD, Foster GR, Arora S et al. Increase in primary liver cancer in the UK, 1979-1994. Lancet 1997 350 : 1142 1143.
10. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996 334 : 693 699.
11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 1917.
12. Lodato F, Mazzella G, Festi D et al. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J. Gastroenterol. 2006 12 : 7239 7249.
13. Dore GD, Wallace J, Locarinini S et al. Hepatitis B in Australia: Responding to a Diverse Epidemic. 2008. Australasian Society for HIV Medicine. Cited June 2009. Available from URL: http://www.ashm.org.au/uploads/Hep-B-in- Australia.pdf
14. Hepatitis C Virus Projections Working Group. Estimates and projections of the HCV epidemic in Australia. Department of Health and Ageing, Australian Government, 2006. Cited June 2009. Available from URL: http://www.health.gov.au/ internet/main/publishing.nsf/content/phd-hepc-estimates-project-06
15. Law MG, Dore GJ, Bath N et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int. J. Epidemiol. 2003 32 : 717 724.
16. Oka H, Kurioka N, Kim K et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990 12 (4 Pt 1 680 687.
17. Curley SA, Izzo F, Gallipoli A et al. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann. Surg. 1995 222 : 375 380 discussion 380-3.
18. Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am. J. Gastroenterol. 1996 91 : 1189 1194.
19. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000 31 : 1019 1021.
20. Senator McLucas J. 2008. Media Release - Rudd Government Acts to Lift Organ Donation Rates. Department of Health and Ageing, Australian Government. Cited June 2009. Available from URL: http://www.health.gov.au/internet/ ministers/publishing.nsf/Content/mr-yr08-jm-jm001.htm
21. Gerard K, Salkeld G, Hall J. Counting the costs of mammography screening: first year results from the Sydney study. Med. J. Aust. 1990 152 : 466, 469 471.
22. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003 52 (Suppl. 3 iii1 8.
23. Australian Medicare Benefits Schedule (1 November 2004 revision). Department of Health and Ageing, Australian Government.